Developer docs
API playgroundTry for free, no card

Search company profiles

Baxter Biopharma Solutions

Full company profile

uuid00yptrl

Namestring
Baxter Biopharma Solutions
Legal namestring
Baxter BioPharma Solutions
Company typeenum
Private
Founded yearint
1931
Descriptiontext

Simtra BioPharma Solutions (formerly Baxter Biopharma Solutions) is a contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals. Founded in 1931 and headquartered in Bloomington, Indiana, the company operates two cGMP-compliant, ISO 14001-certified manufacturing campuses — Bloomington, Indiana (USA) and Halle/Westfalen (Germany) — and distributes manufactured products to patients in more than 120 countries. Its service portfolio spans formulation development, lyophilization cycle development and optimization, rapid technology transfer, fill/finish operations, specialized containment for cytotoxics and highly potent compounds, analytical services, and global regulatory support, with delivery formats including liquid vials, lyophilized vials, and prefilled syringes across drug categories ranging from small molecules to biologics, vaccines, and diluents.

The company's underlying technology platform is built around sterile injectable manufacturing — encompassing aseptic fill/finish, lyophilization, and specialized containment — and is being extended upstream into bioconjugation to deliver integrated drug-substance-to-drug-product solutions, particularly for antibody drug conjugates (ADCs). Capital infrastructure is a defining feature: a recent strategic purchase from Cook Group added a 65-acre property with more than 300,000 square feet of available expansion space adjacent to the Bloomington site, and a new production building has been completed at the German campus. A five-year strategic alliance with MilliporeSigma (the Life Science business of Merck KGaA) combines Simtra's fill/finish expertise with bioconjugation and antibody capabilities to offer an end-to-end ADC manufacturing ecosystem.

Simtra generates revenue through fee-for-service contract manufacturing for pharmaceutical and biotech clients across clinical and commercial stages, supplemented by long-term managed-service commercial supply agreements that produce recurring revenue. Pricing is not publicly disclosed and is negotiated project-by-project based on molecule complexity, batch size, regulatory pathway, and service scope. The go-to-market motion is consultative and enterprise-focused, engaging directly with pharma and biotech decision-makers (VP Manufacturing, CTO-level) through relationship-driven sales cycles, supported by content marketing, industry events, earned media, and LinkedIn presence. The company serves a horizontal segmentation of pharmaceutical and biotech customers, with ADC developers as a strategically emphasized secondary segment. Following its separation from Baxter International, the company now operates as an independent private CDMO under the Simtra brand.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectable manufacturing, contract development manufacturing, aseptic fill finish, lyophilization cycle development, bioconjugation ADC services
Industry2 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Sterile Injectable CDMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Simtra operates as a CDMO providing fee-for-service contract manufacturing to pharmaceutical and biotech companies. Revenue is generated through service contracts for formulation development, fill/finish operations, lyophilization, analytical services, and technology transfer across clinical and commercial stages. The business model is project-based and relationship-driven, consistent with the CDMO/CMO industry standard.

simtra.com
2Commercial Manufacturing Supply
TypeManaged Services
Description

Long-term supply agreements for commercial-stage sterile injectable products, providing recurring revenue from manufacturing scale-up and ongoing production for approved drugs.

simtra.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Baxter Biopharma Solutions (now operating as Simtra BioPharma Solutions) is a contract development and manufacturing organization (CDMO) providing formulation development, lyophilization cycle development, rapid technology transfer, fill/finish operations, specialized containment for potent compounds, analytical services, and global regulatory support for sterile injectable pharmaceuticals. The company manufactures across cytotoxics, highly potent compounds, biologics, vaccines, small molecules, and diluents in liquid vials, lyophilized vials, and prefilled syringes from cGMP-compliant facilities in Bloomington, Indiana (USA) and Halle/Westfalen, Germany, with products distributed to patients in 120+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Products distributed in 120+ countries
+1 more record
Product overview1 text field

Based on the source data, Baxter Biopharma Solutions is mentioned as a participant in fill-finish partnership announcements within the aseptic fill finish market. The company operates in the pharmaceutical contract manufacturing space, specifically in aseptic fill finish services for biologics and vaccines. No detailed product portfolio, modules, or service offerings were extracted from the provided sources.

Product and service1 record
1Formulation Development
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1MilliporeSigma (Life Science business of Merck KGaA, Darmstadt, Germany)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Simtra BioPharma Solutions and MilliporeSigma announced a five-year strategic alliance for antibody drug conjugate (ADC) drug substance and drug product manufacturing services. The alliance enables an integrated ADC offering, combining Simtra's sterile injectable fill/finish expertise with MilliporeSigma's bioconjugation and antibody manufacturing capabilities. The partnership creates an end-to-end solution for ADC development and manufacturing under one ecosystem.

simtra.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Recipharm
TypeDirect peer
Description

European-headquartered CDMO offering sterile injectable fill-finish and other pharmaceutical manufacturing services. Directly comparable on sterile fill-finish capabilities, though with a stronger small-molecule/specialty focus than Simtra.

TypeBroad incumbent
Description

Large-scale biologics contract manufacturer offering drug substance and aseptic fill-finish services. Comparable as a high-capacity, fully integrated biologics CDMO, though primarily Asian-headquartered and with a biologics-skewed portfolio.

TypeDirect peer
Description

One of the world's largest CDMOs offering sterile injectable, biologics, and small-molecule manufacturing. Comparable on end-to-end development-to-commercial services, cGMP infrastructure, and global multi-site footprint serving pharma customers.

TypeDirect peer
Description

European pharmaceutical CDMO with sterile manufacturing, including lyophilization and prefilled syringe capabilities. Comparable on sterile fill-finish service offerings and customer base of mid-to-large pharma.

TypeDirect peer
Description

Global CDMO leader with large-scale sterile injectable fill-finish and biologics manufacturing capabilities, serving many of the same pharmaceutical and biotech customers as Simtra across clinical and commercial stages. Most directly comparable on sterile fill-finish scope and customer base.

6MilliporeSigma
TypeOthers
Description

Life Science business of Merck KGaA providing bioconjugation, antibody manufacturing, and ADC development services. Connected to Simtra via a five-year strategic alliance, and complementary (rather than directly competitive) on the ADC value chain.

TypeDirect peer
Description

Major global CDMO with significant sterile injectable and biologics manufacturing capacity. Comparable on large-scale aseptic fill-finish for innovative pharma, though with a distinct geographic and customer mix.

TypeDirect peer
Description

Through its Patheon pharma services business, Thermo Fisher offers sterile injectable fill-finish and broader CDMO services globally. Directly comparable in serving large pharma customers with sterile fill-finish, formulation, and analytical services.

TypeBroad incumbent
Description

Pfizer's contract manufacturing arm offering sterile injectable and API manufacturing services to external customers. Comparable on sterile injectable capabilities and access to large-pharma-grade cGMP infrastructure.

10Boehringer Ingelheim BioXcellence
TypeDirect peer
Description

Boehringer Ingelheim's biopharmaceutical contract manufacturing business, focused on biologics fill-finish, including for highly potent compounds. Directly comparable on mammalian-based biologics fill/finish and process complexity.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Baxter Biopharma Solutions

Sterile Injectable CDMO Servicesbaxterbiopharmasolutions.com

What Baxter Biopharma Solutions does

Simtra BioPharma Solutions (formerly Baxter Biopharma Solutions) is a contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals. Founded in 1931 and headquartered in Bloomington, Indiana, the company operates two cGMP-compliant, ISO 14001-certified manufacturing campuses — Bloomington, Indiana (USA) and Halle/Westfalen (Germany) — and distributes manufactured products to patients in more than 120 countries. Its service portfolio spans formulation development, lyophilization cycle development and optimization, rapid technology transfer, fill/finish operations, specialized containment for cytotoxics and highly potent compounds, analytical services, and global regulatory support, with delivery formats including liquid vials, lyophilized vials, and prefilled syringes across drug categories ranging from small molecules to biologics, vaccines, and diluents.

The company's underlying technology platform is built around sterile injectable manufacturing — encompassing aseptic fill/finish, lyophilization, and specialized containment — and is being extended upstream into bioconjugation to deliver integrated drug-substance-to-drug-product solutions, particularly for antibody drug conjugates (ADCs). Capital infrastructure is a defining feature: a recent strategic purchase from Cook Group added a 65-acre property with more than 300,000 square feet of available expansion space adjacent to the Bloomington site, and a new production building has been completed at the German campus. A five-year strategic alliance with MilliporeSigma (the Life Science business of Merck KGaA) combines Simtra's fill/finish expertise with bioconjugation and antibody capabilities to offer an end-to-end ADC manufacturing ecosystem.

Simtra generates revenue through fee-for-service contract manufacturing for pharmaceutical and biotech clients across clinical and commercial stages, supplemented by long-term managed-service commercial supply agreements that produce recurring revenue. Pricing is not publicly disclosed and is negotiated project-by-project based on molecule complexity, batch size, regulatory pathway, and service scope. The go-to-market motion is consultative and enterprise-focused, engaging directly with pharma and biotech decision-makers (VP Manufacturing, CTO-level) through relationship-driven sales cycles, supported by content marketing, industry events, earned media, and LinkedIn presence. The company serves a horizontal segmentation of pharmaceutical and biotech customers, with ADC developers as a strategically emphasized secondary segment. Following its separation from Baxter International, the company now operates as an independent private CDMO under the Simtra brand.

Baxter Biopharma Solutions firmographics

Firmographics
Name
Baxter Biopharma Solutions
Legal name
Baxter BioPharma Solutions
Website
https://baxterbiopharmasolutions.com
Company type
Private
Founded year
1931
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Baxter Biopharma Solutions industry classification

Industry
Product category
Sterile Injectable CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Sterile injectable manufacturing
  • Contract development manufacturing
  • Aseptic fill finish
  • Lyophilization cycle development
  • Bioconjugation ADC services

Where Baxter Biopharma Solutions is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Baxter Biopharma Solutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: Simtra operates as a CDMO providing fee-for-service contract manufacturing to pharmaceutical and biotech companies. Revenue is generated through service contracts for formulation development, fill/finish operations, lyophilization, analytical services, and technology transfer across clinical and commercial stages. The business model is project-based and relationship-driven, consistent with the CDMO/CMO industry standard.
  2. Commercial Manufacturing Supply: Long-term supply agreements for commercial-stage sterile injectable products, providing recurring revenue from manufacturing scale-up and ongoing production for approved drugs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Baxter Biopharma Solutions product offering

Product offering

Core offering

Baxter Biopharma Solutions (now operating as Simtra BioPharma Solutions) is a contract development and manufacturing organization (CDMO) providing formulation development, lyophilization cycle development, rapid technology transfer, fill/finish operations, specialized containment for potent compounds, analytical services, and global regulatory support for sterile injectable pharmaceuticals. The company manufactures across cytotoxics, highly potent compounds, biologics, vaccines, small molecules, and diluents in liquid vials, lyophilized vials, and prefilled syringes from cGMP-compliant facilities in Bloomington, Indiana (USA) and Halle/Westfalen, Germany, with products distributed to patients in 120+ countries.

Product overview

Based on the source data, Baxter Biopharma Solutions is mentioned as a participant in fill-finish partnership announcements within the aseptic fill finish market. The company operates in the pharmaceutical contract manufacturing space, specifically in aseptic fill finish services for biologics and vaccines. No detailed product portfolio, modules, or service offerings were extracted from the provided sources.

Differentiator

Problem solved

Functional benefit

Products and services

  • Formulation Development

Quantifiable outcome

  • Products distributed in 120+ countries
  • +1 more outcomes

Companies that use Baxter Biopharma Solutions

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Baxter Biopharma Solutions technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Baxter Biopharma Solutions partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MilliporeSigma (Life Science business of Merck KGaA, Darmstadt, Germany)coreStrategic or Co-development Partner · 1 October 2025Simtra BioPharma Solutions and MilliporeSigma announced a five-year strategic alliance for antibody drug conjugate (ADC) drug substance and drug product manufacturing services. The alliance enables an integrated ADC offering, combining Simtra's sterile injectable fill/finish expertise with MilliporeSigma's bioconjugation and antibody manufacturing capabilities. The partnership creates an end-to-end solution for ADC development and manufacturing under one ecosystem.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Baxter Biopharma Solutions competitors and assessment

Company assessment

Direct peers

  • Recipharm: European-headquartered CDMO offering sterile injectable fill-finish and other pharmaceutical manufacturing services. Directly comparable on sterile fill-finish capabilities, though with a stronger small-molecule/specialty focus than Simtra.
  • Lonza: One of the world's largest CDMOs offering sterile injectable, biologics, and small-molecule manufacturing. Comparable on end-to-end development-to-commercial services, cGMP infrastructure, and global multi-site footprint serving pharma customers.
  • Aenova Group: European pharmaceutical CDMO with sterile manufacturing, including lyophilization and prefilled syringe capabilities. Comparable on sterile fill-finish service offerings and customer base of mid-to-large pharma.
  • Catalent: Global CDMO leader with large-scale sterile injectable fill-finish and biologics manufacturing capabilities, serving many of the same pharmaceutical and biotech customers as Simtra across clinical and commercial stages. Most directly comparable on sterile fill-finish scope and customer base.
  • WuXi STA (WuXi AppTec): Major global CDMO with significant sterile injectable and biologics manufacturing capacity. Comparable on large-scale aseptic fill-finish for innovative pharma, though with a distinct geographic and customer mix.
  • Thermo Fisher Scientific (Patheon): Through its Patheon pharma services business, Thermo Fisher offers sterile injectable fill-finish and broader CDMO services globally. Directly comparable in serving large pharma customers with sterile fill-finish, formulation, and analytical services.
  • Boehringer Ingelheim BioXcellence: Boehringer Ingelheim's biopharmaceutical contract manufacturing business, focused on biologics fill-finish, including for highly potent compounds. Directly comparable on mammalian-based biologics fill/finish and process complexity.

Broad incumbents

  • Samsung Biologics: Large-scale biologics contract manufacturer offering drug substance and aseptic fill-finish services. Comparable as a high-capacity, fully integrated biologics CDMO, though primarily Asian-headquartered and with a biologics-skewed portfolio.
  • Pfizer CentreOne: Pfizer's contract manufacturing arm offering sterile injectable and API manufacturing services to external customers. Comparable on sterile injectable capabilities and access to large-pharma-grade cGMP infrastructure.

Others

  • MilliporeSigma: Life Science business of Merck KGaA providing bioconjugation, antibody manufacturing, and ADC development services. Connected to Simtra via a five-year strategic alliance, and complementary (rather than directly competitive) on the ADC value chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Baxter Biopharma Solutions social profiles

Digital presence

Baxter Biopharma Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Baxter Biopharma Solutions leadership team

Management profile

Number of profiles

Baxter Biopharma Solutions funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Baxter Biopharma Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baxter Biopharma Solutions

What does Baxter Biopharma Solutions do?

Baxter Biopharma Solutions (now operating as Simtra BioPharma Solutions) is a contract development and manufacturing organization (CDMO) providing formulation development, lyophilization cycle development, rapid technology transfer, fill/finish operations, specialized containment for potent compounds, analytical services, and global regulatory support for sterile injectable pharmaceuticals. The company manufactures across cytotoxics, highly potent compounds, biologics, vaccines, small molecules, and diluents in liquid vials, lyophilized vials, and prefilled syringes from cGMP-compliant facilities in Bloomington, Indiana (USA) and Halle/Westfalen, Germany, with products distributed to patients in 120+ countries.

Is Baxter Biopharma Solutions a public or private company?

Baxter Biopharma Solutions is a private company. It is classified as corporate owned and is currently operating.

When was Baxter Biopharma Solutions founded?

Baxter Biopharma Solutions was founded in 1931. It employs 1,001 to 5,000 people.

Where is Baxter Biopharma Solutions based?

Baxter Biopharma Solutions is headquartered in Parsippany, United States, in the North America region.

How does Baxter Biopharma Solutions make money?

Two revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are commercial Manufacturing Supply.

Who are Baxter Biopharma Solutions's main competitors?

Direct peers on record are Recipharm, Lonza, Aenova Group, Catalent, WuXi STA (WuXi AppTec), Thermo Fisher Scientific (Patheon) and Boehringer Ingelheim BioXcellence. Broad incumbents are Samsung Biologics and Pfizer CentreOne. MilliporeSigma is listed as an others.

Does Baxter Biopharma Solutions have an API?

No public API is recorded for Baxter Biopharma Solutions.

What industry is Baxter Biopharma Solutions in?

Baxter Biopharma Solutions's product category is Sterile Injectable CDMO Services. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comUnited States Contract Pharmaceutical Packaging Industry Sector Growth, Trends & Forecast 2025-2032 | Leading Pharma Companies - Aphena Pharma Solutions, ROPACK INC, Wasdell Packaging Group, Baxter BiThe contract pharmaceutical packaging market is projected to grow from US$15.21 billion in 2024 to US$26.59 billion by 2032, a CAGR of 7.23%. North America leads with a 35% share, and plastics and polymers are expected to dominate over 30% of the market.ContractpharmaSterile Injectable Contract Manufacturing MarketGrand View Research reports that the global sterile injectable contract manufacturing market was valued at $12.89 billion in 2022 and is projected to grow at a CAGR of 12.1% through 2030, driven by biopharmaceutical development and chronic illness prevalence. The report highlights significant regional growth in Asia Pacific due to regulatory reforms in China and India, while North America retains the largest market share supported by established contract manufacturers like Baxter Biopharma and Catalent Inc. Conversely, the industry faces headwinds from geopolitical tensions affecting Russian operations and declining drug approval rates linked to global inflation.ContractpharmaAdvent International, Warburg Pincus Name Franco Negron CEO of BioPharma SolutionsAdvent International and Warburg Pincus named Franco Negron CEO of BioPharma Solutions, a sterile contract manufacturing firm. The divestiture from Baxter is expected to close in the second half of 2023. Negron previously served as CEO of ApiJect Systems America and held roles at Thermo Fisher and Patheon.ContractpharmaBaxter Divests BioPharma Solutions Biz to Advent, Warburg Pincus for $4.25BBaxter signed a definitive agreement to divest its BioPharma Solutions business to Advent International and Warburg Pincus for $4.25 billion in cash, with net after-tax proceeds estimated at $3.4 billion. The deal includes manufacturing facilities and about 1,700 employees, and is expected to close in the second half of 2023. Baxter plans to use the proceeds to reduce its debt.Business Wire BlogBaxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 BillionBaxter signed a definitive agreement to sell its BioPharma Solutions business to Advent International and Warburg Pincus for $4.25 billion in cash, with net after-tax proceeds estimated at about $3.4 billion. The deal is expected to close in the second half of 2023, and Baxter plans to use the proceeds to reduce debt.GlobeNewswireBiopharmaceuticals Contract Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)The biopharmaceuticals contract manufacturing market is projected to grow at a CAGR of nearly 7.5% from 2023 to 2028. The COVID-19 pandemic has significantly impacted the market, with Baxter BioPharma Solutions entering an agreement to provide sterile manufacturing services for Novavax's COVID-19 vaccine candidate. Increasing outsourcing and R&D investments are key drivers, while regulatory and logistics costs pose challenges.Business Wire BlogBaxter Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing FacilityBaxter announced a $100 million expansion of its sterile fill/finish facility in Halle/Westfalen, Germany, operated by BioPharma Solutions. Construction is expected to begin in 2022 and complete in 2024, adding lyophilization and aseptic syringe filling capabilities. The investment aims to meet growing demand for pre-filled syringes in Europe and the U.S.PR NewswireVaccine Contract Manufacturing Market Report 2016-2026 : Leading Countries, Technologies and CompaniesVisiongain released a market research report forecasting the vaccine contract manufacturing market to reach $1,047.3 million by 2019, driven by increasing demand for therapeutic vaccines and an aging population. The study analyzes revenue projections for major global markets including the US, China, and India, while profiling key industry players such as Lonza, Catalent, and Baxter BioPharma Solutions.